Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress

Cancer Discovery
Victor Moreno GarciaJohann S de Bono

Abstract

Current anticancer drug development still largely follows the classic designs developed for chemotherapeutic agents over the past 4 to 5 decades, remaining slow, costly, and inefficient, with continuing high risks of costly late drug attrition. A Pharmacologic Audit Trail has been described to decrease these risks, incorporating pharmacokinetic, pharmacodynamic, intermediate efficacy endpoints, as well as patient stratification molecular biomarkers. Molecular biomarker-based patient selection in hypothesis-testing early clinical trials is critical to clinically qualify putative predictive biomarkers for rationally designed, molecularly targeted drugs as early as possible. Nevertheless, major concerns have been raised about the impact of using such biomarkers in early trials, in view of the costs and time involved to develop multiple certified assays for clinical use. The rapid evolution of novel technologies of utility to this field, such as next-generation sequencing and circulating tumor-cell isolation, makes these valid concerns of critical importance. We therefore propose a more efficient parallel predictive biomarker and clinical anticancer drug development process to deal with the obstacles hindering progress.

References

Mar 9, 2006·Health Affairs·Christopher P Adams, Van V Brantner
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pingfu FuMark Schluchter
Jun 11, 2010·Nature Reviews. Cancer·Timothy A YapJohann S de Bono
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Jan 6, 2011·British Journal of Cancer·B BasuJ S de Bono

❮ Previous
Next ❯

Citations

Nov 15, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·G ArgilésJ Tabernero
Apr 5, 2012·Nature Reviews. Clinical Oncology·Jordi RodónJosep Tabernero
Mar 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard L SchilskyBarbara A Conley
Nov 29, 2015·Seminars in Oncology·Jorge Zeron-MedinaJordi Rodon
Nov 26, 2014·Nature Reviews. Clinical Oncology·Armand de GramontStanley R Hamilton
Sep 25, 2016·Seminars in Oncology·Udai Banerji, Paul Workman
May 10, 2013·Clinical Chemistry·Michael J Duffy, John Crown
Mar 16, 2013·Current Opinion in Oncology·Rodrigo DienstmannJosep Tabernero
Jan 1, 2012·American Society of Clinical Oncology Educational Book·Rodrigo DienstmannJosep Tabernero
Sep 26, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Victor Moreno GarcíaStan B Kaye

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.